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The enzyme succinate dehydrogenase (SDH) functions in the citric acid cycle and loss of function 
predisposes to the development of phaeochromocytoma/paraganglioma (PPGL), wild type 
gastrointestinal stromal tumour (wtGIST) and renal cell carcinoma. SDH-deficient tumours are most 
commonly associated with a germline SDH subunit gene (SDHA/B/C/D) mutation but can also be 
associated with epigenetic silencing of the SDHC gene. However, clinical diagnostic testing for an SDHC 
epimutation is not widely available. The objective of this study was to investigate the indications for 
and the optimum diagnostic pathways for the detection of SDHC epimutations in clinical practice. SDHC 
promoter methylation analysis of 32 paraffin embedded tumours (including 15 GIST and 17 PPGL) 
was performed using a pyrosequencing technique and correlated with SDHC gene expression. SDHC 
promoter methylation was identified in 6 (18.7%) tumours. All 6 SDHC epimutation cases presented 
with SDH deficient wtGIST and 3/6 cases had multiple primary tumours. No case of constitutional SDHC 
promoter hypermethylation was detected. Whole genome sequencing of germline DNA from three 
wtGIST cases with an SDHC epimutation, did not reveal any causative sequence anomalies. Herein, we 
recommend a diagnostic workflow for the detection of an SDHC epimutation in a service setting.
Loss of function of the succinate dehydrogenase (SDH) enzyme complex leads to intracellular accumulation of 
succinate as oxidative dehydrogenation of succinate to fumarate in the citric acid cycle is interrupted. Succinate 
can function as an ‘oncometabolite’ and drive tumourigenesis by competitively inhibiting 2-oxyglutarate depend-
ent enzymes including prolyl hydroxylase and DNA and histone demethylase enzymes resulting in a pseudohy-
poxic transcriptional response1 and DNA and histone hypermethylation2.
Biallelic inactivation of one of the four SDH subunit genes (SDHA, SDHB, SDHC, SDHD) is the most common 
mechanism causing SDH deficient (dSDH) tumours. Germline genetic testing for germline SDHx mutations is 
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now considered best practice for patients presenting with i) PPGL3, ii) wild type gastrointestinal stromal tumours 
(wtGIST)4 and iii) specific histopathological subtypes of renal cell carcinoma5. wtGIST are defined as GIST that 
are negative for KIT and PDGFRA somatic gene mutations and account for 15% of adult and 85% of paediat-
ric GIST. Biallelic inactivation of any of the SDHx genes, most commonly results in destabilisation of the SDH 
enzyme complex, which can be detected by loss of staining for the SDHB protein on IH6 and therefore wtGIST 
can be further classified based on the loss or preservation of SDHB protein expression on immunohistochemis-
try as a surrogate marker for loss of function of the SDH complex. Importantly, SDH deficient wtGIST (dSDH 
wtGIST) account for approximately 7–10% of all GIST4,7.
Identification of a germline pathogenic variant in SDHB informs a higher risk of a malignant PPGL2 and 
detection of a germline SDHx mutation facilitates personalised surveillance, family screening and potentially the 
choice of therapy for metastatic disease1,2. In addition to testing for germline SDHx variants, immunostaining for 
SDHB and SDHA is a valuable approach for identifying dSDH tumours6.
It is now recognized that in a subset of dSDH tumours, SDH inactivation results from promoter hyper-
methylation and epigenetic silencing of the SDHC gene2,6–10. SDHC promoter hypermethylation has been most 
frequently found in dSDH-wtGIST8–13 with up to a third of all of cases having SDHC promoter methylation2. 
Distinguishing dSDH tumours with germline SDHx mutations from those with SDHC hypermethylation only 
is beneficial because i) the relatives of patients with a germline SDHx mutation are at increased tumour risk and 
ii) an SDHC epimutation is potentially reversible (clinical trials have been initiated to investigate demethylating 
agents in such cases (ClinicalTrials.gov Identifier: NCT03165721)).
SDHC epimutations appear to be unique to specific tumour types (e.g wtGIST and PPGL)8 but further study is 
required to determine whether SDHC epimutations might occur in tumours with an associated hypermethylation 
phenotype other than SDH deficient wt GIST and PPGL. IDH1 mutant gliomas have previously been associated 
with a global hypermethylation phenotype due to inhibition of alpha ketoglutarate dependent de-methylation 
enzymes14 and therefore IDH1mutant gliomas are a useful tumour type to test the hypothesis that SDHC pro-
moter hypermethylation is unique to specific tumour types.
Despite the implications for patient management and family testing and screening, diagnostic testing for 
SDHC epimutations has not been adopted as routine clinical practice because the indications for testing and a 
suitable methodology for a clinical service laboratory have not been well defined8. The aims of this study were; i) 
to investigate a pyrosequencing-based assay for the diagnosis of SDHC promoter methylation and ii) to determine 
the role for SDHC epimutation testing in a clinical diagnostic pathway using pooled data from this study and 
available literature.
Methods
Clinical sample collection. Cases were ascertained from the Neuroendocrine Tumour, the National 
Pediatric and Adult wild type GIST (PAWS GIST UK) and clinical genetics clinics at Cambridge University 
Hospital NHS Foundation Trust. Details of clinical phenotype, family history and germline molecular testing 
results were collated from patient records.
study design. All cases of identified PPGL wtGIST, for whom formalin fixed paraffin embedded (FFPE) 
tumour blocks were available, were considered for inclusion in the study. All participants (and or legal guardians) 
gave written informed consent. 32 cases (15 wtGIST and 17 PPGL) were included in the analysis. For each case 
studied, DNA was extracted from FFPE tumour tissue and adjacent normal tissue (31/32 cases) and blood when 
available (21/32 cases). mRNA was extracted from FFPE tumour tissue and adjacent normal FFPE tissue. SDHB 
immunohistochemistry (IH) was performed on all 32 samples. Tumour samples with evidence of SDHB preser-
vation on SDHB IH were included in SDHC promoter methylation analysis in order to confirm if SDHB IH was 
a sensitive triaging test for the diagnosis of an SDHC epimutation.
Methylation analysis was performed on DNA extracted from FFPE tumour and matched normal tissue/blood. 
SDHC expression analysis was performed on RNA extracted from FFPE tumour and matched normal tissue and 
finally sequencing of tumour DNA was performed to identify somatic SDHx mutations.
A further 17 IDH1 mutant glioma samples (anonymised tumour DNA from consented patients provided by 
Professor Colin Watts) were included in the study.
Germline and tumour genetic sequencing. Clinical germline DNA sequencing. DNA was extracted 
from peripheral blood samples according to standard protocols. Next generation sequencing of a clinical gene 
panel including; SDHA, SDHB, SDHC, SDHD, KIT, PDGFRA and NF1 (for GIST) and SDHA, SDHB, SDHC, 
SDHD, SDHAF2, MAX, TMEM127, VHL, RET, FH for (PPGL) was performed by the laboratory staff at 
Cambridge University Hospital NHS Foundation Trust or Birmingham Women’s and Children’s Hospital NHS 
Trust using the TrusightOne or Trusight Cancer sequencing panels (Illumina Inc., UK).
An average coverage depth of >20 fold was achieved for 98% of the regions sequenced. All detected variants 
were confirmed by Sanger sequencing. Whole exon deletions and duplications and large rearrangements are not 
detected using this method and multiple ligation probe analysis (MLPA) was performed for VHL, SDHB, SDHC 
and SDHD.
Tumour DNA sequencing using a custom gene panel. Tumour sequencing was performed on those cases with 
sufficient DNA quantity following methylation analysis (27/32 cases of PPGL/GIST and 17 gliomas) by the staff 
at the Stratified Medicine Core Laboratory within the Department of Medical Genetics, Cambridge University. 
Sequencing was performed using a custom panel based on the Ion AmpliSeq™ 142 Cancer Hotspot Panel v2 
(catalogue number 4475346).
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Variant filtering was performed on variant calling files (VCF). Variants were removed if the variant allele 
frequency was <10% or the minor allele frequency (MAF) greater than 0.1% in EVS6500 and/or 1000 genome 
project (www.internationalgenome.org). Synonymous variants were removed as presumed not to be patho-
genic. Those variants that had coverage of less than two standard deviations below the mean coverage were also 
removed.
Data extracted from whole genome sequencing. Whole genome sequencing (WGS) was performed on germline 
DNA from three cases as part of the NIHR Rare Disease Bioresource project and sequencing data from two of the 
three patients was included in a recent publication15. Data was filtered to include data in the regions of interest: 
the SDHC promoter region and five genes involved in DNA methylation maintenance and regulation: TET1, 
TET2, TET3, DNMT3A and DNMT3B.
The variants were annotated with variant effect predictor and filtered on i) minor allele frequency of <0.1 or 
absent in 1000 genome project (www.internationalgenome.org) and UK10K (https://www.uk10k.org), ii) conse-
quence including; truncating, missense, splice site and in frame deletion and insertion variants and iii) quality 
including; a read depth of >10 and variant allele frequency of >0.3. All filtered variants were then individually 
interrogated and assigned pathogenicity based on American College of Medical Genetics and Genomics (ACMG) 
criteria.
A comparison of variant allele frequencies in our samples compared to a control group with low neoplas-
tic risk within the bio resource project (NIHR rare disease controls, n = 4053), was also performed and calcu-
lated using a Fishers exact test and corrected for a false discovery rate using the Benjamini-Hochberg procedure. 
Finally, cases were evaluated for structural variants (SV) including copy number variation, using the SV calling 
tools; Canvas and/or Manta16,17.
Tissue dissection for DNA and RNA isolation. Pre-selected paraffin blocks containing tumour and 
adjacent normal tissue were used for nucleic acid extraction. Tumour tissue and normal tissue suitable for DNA 
isolation was identified by an experienced molecular histopathologist (OG). Tumour cell content in the tumour 
enriched areas ranged between 50–80%. Normal tissue used as control was histologically confirmed to be tumour 
free. 6–10 µm thick FFPE sections were mounted on glass slides. Tumour and normal tissue were scraped of the 
slides barring a security margin between tumour and normal of 2 mm.
Bisulfite modification. The assay was proven to work reliably with 10 ng input DNA, however 500 ng of 
DNA was used as a standard for bisulfite modification with the Zymo Research EZ DNA Methylation kit (D5001) 
according to the manufacturer’s instructions. Bisulfite converted DNA was eluted from the spin colums with 
50ul of elution buffer and directly processed for PCR or frozen at −20 °C. Complete bisulfite modification was 
monitored by an internal bisulfite control position after 5 consecutive cytosines in the genomic sequence in the 
pyrosequencing assay.
Polymerase chain reaction and pyrosequencing. CpG27 was chosen over CpG17 as the CpG27 island 
was located proximal to the transcription start site for the SDHC gene. A 198 bp sized PCR amplicon in the 
CpG27 island located in the SDHC promoter region of the SDHC gene was amplified from 50 ng of CT bisulfite 
converted DNA with 375 nM of forward primer (GAAAATAATTAGTAAATTAGTTAGGTAG) and 187.5 nM 
of biotinylated reverse primer (ACTAAAATCACCTCAACAACAAC) with the Qiagen PyroMark kit (Qiagen 
978703). The PCR conditions were 7 min at 95 °C, followed by 20 sec at 95 °C, 30 sec at 53 °C, and 20 sec at 72 °C 
for 42 cycles, and an end incubation at 72 °C for 5 min. The resulting PCR amplicon was quality assessed for purity 
and yield on a 2% agarose gel. A nested sequencing primer (GTTATATGATATTTTTAATTT) at a concentration 
of 500 nM was used to analyse 12 CpGs in 10ul of the sample on the Qiagen Q24 pyrosequencer. Fully methyl-
ated and unmethylated human control DNA that had been treated with bisulfite were used as controls on each 
pyrosequencing run.
Ten percent of the bisulfite conversion eluate (approximately 50 ng) was used as a PCR template. The lower 
detection limit of the assay was 10% eluate of 10 ng input DNA for bisulfite conversion (approximately 1 ng) for 
fresh frozen and DNA isolated from FFPE. Methylation percentage differences of 25% were reliably detectable for 
10 ng and 50 ng of template bisulfite converted DNA.
Development of a clinical diagnostic assay for SDHC methylation. In order to facilitate the transla-
tion of SDHC promoter methylation analysis into clinical practice we set out to develop an assay using technology 
that is available in a service setting and that would provide robust results on DNA extracted from FFPE. Tumours 
from 32 patients with wtGIST15 and PPGL17 and a further 17 glioma tumour samples were studied.
Additional methods in supplementary data: (i) Tumour DNA extraction, (ii) Analysis of TCGA tumour 
set, (iii) RNA extraction, (iv) cDNA synthesis, (v) Expression Analysis with quantitative RT PCR, (vi) Statistical 
analysis.
All methods were performed in accordance with the relevant guidelines and recommendations.
ethical approval and consent to participate. All participants gave written informed consent for study 
participation and publication and the study was approved by Cambridge South Research Ethics Committee (REC 
Reference Number: CA/5175).
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Results
Genotype and clinical phenotype of patient cohort. wtGIST and PPGL cases. The mean age 
of tumour diagnosis was 36.6 years (range 15–71, SD 18.8). The fifteen cases of wtGIST included 10 cases of 
dSDH-wtGIST and 5 cases of SDH preserved wtGIST, as defined by loss or preservation respectively of SDHB 
protein expression on immunohistochemistry (Table 1). The 17 PPGL cases included 13 SDH preserved PPGL, 
Case Age Sex Germline variants Phenotype
Mean tumour 
methylation 
index (MI%) SDHB IH
001 23 F Negative* Metastatic wtGIST 73% Loss
002 15 F Negative* Metastatic wtGIST 45% Loss
003 21 F Negative* Metastatic wtGIST 68% Loss
004 24 F SDHC c.380A>G, p.His127Arg
wtGIST + Oesophageal 
leiomyoma + Pulmonary 
chondroma
38% Loss
019 16 F SDHA c.91C>T p.Arg31Ter Metastatic wtGIST 3% Loss
020 37 M SDHB c.137G>A p.Arg46Gln
Metastatic 
wtGIST + Carotid PGL 1% Loss
021 21 F
SDHD c.34G>A 
(p.Gly12Ser) (benign 
polymorphism)**
Metastatic 
wtGIST + Thoracic PGL 49% Loss
022 27 F SDHC c.148C>T p.Arg50Cys* wtGIST + Abdominal PGL 32% Loss
023 29 F Negative wtGIST 7% Preserved
024 36 F NF1 c.4421delG p.Tyr794Ter wtGIST 4% Preserved
027 22 F Negative wtGIST 1% Preserved
028 24 F SDHA c.1909-2A>G Metastatic wtGIST 2% Loss
030 30 M Negative wtGIST 1% Preserved
031 57 M Negative wtGIST 1% Preserved
032 67 M SDHD c.296delT, p.Leu99Profs*36 wtGIST 2.5% Loss
Table 1. Clinical and molecular profile of wtGIST. *MLPA performed. **Benign polymorphism.
Case Age Sex
Germline 
variants Phenotype
Mean tumour 
methylation index 
(MI%) SDHB IH
005 22 F SDHB c.380G>T p.Ile127Ser Abdominal PGL 5.5% Loss
006 27 M SDHB c.302G>A p.Cys101Tyr
Abdominal 
PGL + Carotid PGL 1% Loss
007 15 M Negative* Abdominal PGL 2% Loss
008 21 M Negative* PC 2% Preserved
009 40 F Negative* Metastatic PC 1% Preserved
010 38 F NF1 c.1318C>T p.Arg440Ter PC 1% Preserved
011 78 F Negative* PC 1% Preserved
012 38 F RET c.1900T>A p.Cys634Ser PC 1% Preserved
013 30 M Negative* PC 1% Preserved
014 62 M Negative* PC 2% Preserved
015 37 F RET c.1900T>A p.Cys634Ser PC 1% Preserved
016 52 M Negative* PC 2% Preserved
017 78 M Negative* PC 6% Preserved
018 45 M Negative* Abdominal PGL 5% Preserved
025 72 M Negative* PC 1% Preserved
026 25 F VHL c.499C>G p.Arg167Gly PC 1% Equivocal
029 27 F Negative* Metastatic PC 2% Preserved
Table 2. Clinical and molecular profile of PPGL study participants. *MLPA performed.
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3 dSDH-PPGL and 1 PPGL with an equivocal SDHB result (diffusely weak SDHB expression) (case # 026) 
(Table 2). Thirteen participants were male, 19 female and nine cases had metastatic disease (Tables 1 and 2). Five 
patients had a clinical history of multiple primary tumours (Tables 1 and 2).
A likely pathogenic or pathogenic germline variant was identified in 12/32 patients (37.5%; 6/15 GIST and 
6/17 PPGL). No CNV was identified by MLPA testing in the cohort.
Methylation analysis by pyrosequencing of tumour DNA from wtGIST and PPGL cohort. The 
% methylation at each of the 12 CpG’s in CpG island 27(CpG27) in the promoter region of SDHC was tested. 
The percentage methylation ranged between 1% and 73% but was highly correlated within an individual tumour 
sample with no significant variability detected across individual CpGs (p = 0.08) (see Fig. 1). A mean % methyl-
ation index (MI = % of methylated CpGs) of 2.2% (±SD 1.98) across 12 CpG’s, was detected in all but 6 tumour 
samples (Table S1). The mean MI in these six tumours was 50.8% (±SD 16.4) (Fig. 1B) (cases: #001, #002, #003, 
#004, #021, #022).
All cases identified as having an SDHC epimutation in this study had a dSDH wtGIST as the presenting phe-
notype. Comparing 6 tumours with evidence of SDHC hypermethylation to those with low methylation revealed 
statistically significant associations with wtGIST (6/15 versus 0/17 PPGL; P = 0.005), female sex (6/19 versus 0/13 
males; P = 0.02); metastatic disease (5/6 versus 5/26 (P = 0.035), younger age at diagnosis (mean age 24 years ver-
sus mean age 39.2 years) (P = 0.0002) and multiple primary tumours (3/6 versus 2/26, P = 0.03). No significant 
association was found for the presence of a germline pathogenic SDHx variant (P = 0.2).
Methylation analysis by pyrosequencing of blood and adjacent normal tissue DNA from 
wtGIST and PPGL cohort. The purpose of this analysis was to further investigate whether SDHC promoter 
hypermethylation is a constitutional, mosaic or somatic event.
Pyrosequencing of blood DNA was performed on 22/32 (69%) wtGIST and PGL cases and matched normal 
tissue for 31/32 cases (97%). No evidence of SDHC promoter hypermethylation was detected in blood or normal 
tissue (MI <10% in all samples) including the 6 samples with tumour SDHC hypermethylation. No statistically 
significant difference was identified between the mean MI in blood DNA or adjacent normal tissue for those cases 
identified as having tumour hypermethylation compared with those cases without tumour methylation (p = 0.6) 
(Fig. 2A).
As expected, a significant difference was noted for the MI in the tumour compared to the adjacent normal tis-
sue for the 5 hypermethylated tumour cases for which adjacent normal tissue was available for testing (p = 0 .003) 
(Fig. 2A). ROC curve analysis (see Supplementary Data and statistical methods) demonstrated that a methylation 
of >8.5% separated the cases with an identified epimutation and silencing of SDHC from those without (AUC 
1.0, p = < 0.0001).
Analysis of SDHC gene expression in tumour tissue from wtGIST and PPGL cohort. To deter-
mine whether SDHC promoter methylation was associated with transcriptional silencing, analysis of SDHC 
mRNA in both tumour tissue and adjacent normal tissue was performed in 31/32 cases. In 5/5 tumour samples 
with SDHC hypermethylation the mean fold difference was −6.41(SD 5.4) (Fig. 2B) compared to 1.41 (SD 4.41) 
in 26 tumours without SDHC hypermethylation (P = 0.0002) (Figure S1).
Tumour sequencing and additional functional analysis for SDH deficiency in the hypermethylated 
cases. Tumour sequencing was performed on 4/6 (#001, #002, #003, #004) cases with evidence of SDHC 
hypermethylation and no somatic SDHx variants were detected. SDHB immunohistochemistry was performed 
Figure 1. Figure (A) illustrates the distribution of methylation across the 12 individual CpG’s for the six cases 
demonstrated to have SDHC promoter methylation (epimutant cases), and the wt GIST, glioma and PPGL cases 
with no SDHC epimutation. Figure (B) demonstrates the methylation levels across the 12 individual CpG’s for 
the six epimutated cases (#001, #002, #003, #004, ##021, #022).
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on all tumours and loss of SDHB expression was confirmed in all 6 cases with SDHC hypermethylation (Table 1, 
examples for #001 and #003 displayed in Fig. 3A,B).
Data extracted from whole genome germline sequencing analysis (WGS) of hypermethylated 
cases. WGS data was analysed for three cases with tumour SDHC hypermethylation for whom sufficient DNA 
was available (cases; #002, #021 and #022). No candidate pathogenic structural or single nucleotide variants 
were identified in these three cases in the SDHC locus (between 161314257-161375340) containing the SDHC 
promoter, exons and 3′UTR. In the absence of an in cis genetic cause, additional analysis for potential pathogenic 
variants in genes implicated in genome methylation (TET1, TET2, TET3, DNMT3B, DNMT3A, DNMT1), was 
performed.
Figure 2. Figure (A) shows the difference in the mean % methylation of the SDHC promoter locus across 12 
CpG’s in the tumour of the six hypermethylated cases and tumours of the non-epimutant cases and blood DNA 
and normal tissue of cases with and without an identified SDHC epimutation. Figure (B) shows reduced SDHC 
expression in the tumour versus normal tissue of 5/6 cases with an identified SDHC epimutation.
Figure 3. Figure (A) and (B) shows loss of SDHB protein expression on immunohistochemical analysis of the 
primary wtGIST tumour in case #001 and #003 respectively. In Figure (B) SDHB expression is preserved in 
adjacent normal tissue as highlighted by the red arrow. Figure (C) shows a pulmonary chondroma in case #021 
as demonstrated by the white arrow and Figure (D) demonstrates the histology of a pulmonary chondroma 
from case #004, with evidence of normal collapsed lung tissue illustrated by the black arrow and chondrocytes 
in the tumor marked by the red arrow.
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10/965 filtered variants (in test and control samples) were detected in 3 genes (Table S2). A comparison of the 
identified variant frequencies in the three SDHC hypermethylation samples compared to 4053 control genomes 
with low neoplastic risk (from the NIHR Rare Diseases BioResource BRIDGE project) did not yield any statisti-
cally significant findings (Benjamini Hochberg correction for a false discovery rate of p values was applied and 
based on 965 tested hypotheses).
None of the variants identified in the SDHC methylation cases were considered to be pathogenic by ACMG 
criteria. A missense variant of uncertain significance in TET2 (p.Ile1762Val) was identified in all three cases with 
SDHC promoter hypermethylation, but this variant was absent from 1000 genomes and UK10K databases and 
was identified in 1876/4053 controls (Table S2).
Investigating SDHC hypermethylation in non PPGL and wtGIST tumour sets. To further inves-
tigate the apparent specificity of SDHC epimutations in dSDH wtGIST we explored whether SDHC epimutations 
might occur in non-wtGIST tumours with (a) DNA hypermethylation or (b) low SDHC expression in order to 
test the hypothesis that an SDHC epimutation is specific to particular tumour types and/or is not a consequence 
of generalised tumour DNA hypermethylation.
Firstly we undertook SDHC promoter methylation analysis on 17 IDH1 mutant glioma samples. IDH1 mutant 
gliomas have previously been associated with a global hypermethylation phenotype due to inhibition of alpha 
ketoglutarate dependent de-methylating enzymes20. The mean SDHC promoter methylation in the IDH1 mutant 
glioma samples was 2% (±SD 1.28, range 1–4%) (Fig. 1A and Table S3).
Secondly, from non-wtGIST tumours with SDHC gene expression data and sequencing data from cancer 
genomic studies (accessed at http://www.cbioportal.org/), we identified 25 tumour samples with very low SDHC 
transcript levels and no SDHC mutation (Table S4). Methylation array (Illumina 450k) data for these 25 tumours 
was accessed and beta values for 13 SDHC promoter probes inspected. None of the tumours showed evidence of 
SDHC promoter hypermethylation (Table S4).
Discussion
A search of PubMed (using the terms SDHC and methylation or epimutation) identified 8 publications contain-
ing 34 cases of SDHC promoter region hypermethylation in a variety of tumour types including dSDH wtGIST, 
sympathetic (PGL) and parasympathetic (HNPGL) paragangliomas1,9,10,12,13,18 (Table S5). The majority of patients 
(94%, 32/34) identified with SDHC hypermethylation had a dSDH-wtGIST and 53% (18/34) of these cases also 
had an additional tumour(s) (Table S5).
Phenotype of SDHC epimutation cases detected in the present study. We identified SDHC 
promoter region methylation in 6/15 wtGIST (all 6 cases were dSDH-wtGIST) but none of the 17 PPGL or 
SDH-preserved-wtGIST (3/15 wtGIST). All SDHC hypermethylation cases were female and were significantly 
younger than patients without an SDHC epimutation.
Combining our results with previously published series (see Table S5), the association with dSDH-wtGIST 
(alone or as the presenting feature of a multi-tumour syndrome), female gender and young age at diagnosis is 
maintained. Rare reports of isolated sympathetic and parasympathetic PGL with an SDHC epimutation have also 
been published (Table S5).
In two of the cases reported here, somatic SDHC promoter methylation was detected in the presence of 
a germline pathogenic SDHC variant. This would be consistent (though not proven) with a two hit model of 
tumourigenesis in which SDHC hypermethylation resulted in silencing of the wild-type allele in the tumour. Two 
of the cases with a germline SDHC mutation had multiple tumours including case #004 (Fig. 3C,D). The associa-
tion of synchronous or metachronous gastric wtGIST, PPGL and pulmonary chondroma (PCHO) is referred to as 
Carney triad whereas the combination of GIST and PPGL is designated as the Carney-Stratakis syndrome (CSS) 
or dyad. Although it was previously suggested that PCHO occurred exclusively in CT (a non-inherited disorder), 
this study and others11,19 have demonstrated that the triad of wtGIST, PPGL and PCHO can occur in association 
with a germline SDHx mutation and highlights the overlapping features of CT and CSS19–21. However, we did not 
(from interrogation of TCGA, literature and original data) find evidence that SDHC promoter methylation occurs 
outside of wtGIST and, occasionally, PGL.
We identified 4 cases of tumour SDHC promoter methylation with no detectable germline or somatic SDHC 
mutations. Furthermore there was no evidence of a germline SDHC epimutation. In such cases the SDHC pro-
moter hypermethylation might be a somatic event as occurs in many types of cancer and multiple tumour sup-
pressor genes22. In the case of the mismatch repair gene MLH1, somatic MLH1 promoter methylation is relatively 
common in older individuals with colorectal cancer with microsatellite instability but there are rare cases of 
patients with a constitutional MLH1 epimutation who present at a younger age23. In contrast to MLH1, there 
has been no evidence to date that SDHC epimutations may result from in cis promoter region genetic variants24, 
although some studies have described mosaic constitutional SDHC promoter hypermethylation in association 
with tumour hypermethylation8. In the absence of a detectable in cis or in trans genetic variant in these cases, low 
level postzygotic tissue mosaicism for SDHC promoter hypermethylation, provides an alternative hypothesis for 
this multiple tumour phenotype at a young age.
Translating the diagnosis of an SDHC epimutation into clinical practice. A primary aim of this 
study was to develop a proposed methodology for diagnostic SDHC promoter methylation testing in a clinical 
setting. We developed a pyrosequencing-based method because it is well established on FFPE material, allows 
a low level variant detection and is frequently used in diagnostic pathology services for other types of somatic 
methylation analysis (e.g. MGMT promoter methylation analysis in glioma). Our method worked well on DNA 
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extracted from archived routine diagnostic FFPE material (an important consideration as fresh frozen tumour is 
rarely available) and pyrosequencing is less expensive compared to alternative methods e.g. methylation arrays.
We found that the methylation status of 12 CpG’s in CpG27 in the promoter region of the SDHC gene could 
be accurately assessed and that detection of hypermethylation of the SDHC promoter correlated with reduced 
SDHC mRNA on mRNA extracted from the same FFPE tissue block. Recently described methods for the detec-
tion of ex-vivo and in vivo succinate accumulation are useful adjuncts to SDHB IH for the detection of SDH 
deficiency25,26. However, these methods cannot identify the cause of SDH deficiency. The authors recommend that 
whenever possible, cases with SDHC promoter hypermethylation should be analysed by RT-PCR of both tumour 
and adjacent normal tissue to confirm silencing of SDHC in the tumour tissue.
Given that SDHB immunohistochemistry is a relatively accessible and sensitive test, this should be consid-
ered as a first-line triaging test for the detection of SDH deficiency in PPGL and wtGIST21. We recommend that 
germline genetic testing is always considered as the next diagnostic step in dSDH tumours to rule out a poten-
tial syndromic cause. If germline genetic testing (including MLPA) is negative and SDHB IH suggests loss of 
SDHB protein expression, the first step for PPGL should be somatic sequencing27 to investigate for somatic SDHx 
or VHL mutations, which can account for loss of SDHB protein expression6. However, as SDHC epimutations 
are more frequent in wtGIST than in PPGL, we recommend SDHC promoter methylation analysis as the next 
step after germline genetic testing for wtGIST (Fig. 4B). If an SDHC epimutation is diagnosed, somatic tumour 
sequencing should be performed to identify a co-existing somatic SDHx mutation, which may affect the efficacy 
of any potential demethylating therapy (Fig. 4).
Importantly, a number of potential limitations in the diagnosis of SDHC methylation using pyrosequencing 
methods on FFPE tumour tissue, were encountered over the course of this study. Identification of these pitfalls 
has prompted the following practical recommendations; i) using a minimum input of 50 ng of bisulfite converted 
DNA for the PCR and ii) a minimum volume of 10 microlitre of the PCR product for pyrosequencing can min-
imize the risk of false elevations in methylation, iii) fully methylated and unmethylated human control DNA, 
treated with bisulfite should be used as external controls on each pyrosequencing run and iv) the use of matched 
normal tissue is useful as an internal control to account for any false elevation in methylation which may have 
been caused by the long term paraffin storage. Limitations of this study also include the retrospective study design 
and relatively small sample size and diagnostic laboratories wishing to adopt the methodology described herein 
will need to undertake a formal clinical validation study before implementing it for clinical diagnostic use.
In conclusion, the results from our literature review, experimental studies and interrogation of the TCGA data, 
suggest that SDHC epimutations are rare in tumours other than wtGIST and PPGL. Improving the accessibility of 
clinical diagnostic testing for SDHC promoter methylation will facilitate the management of patients with wtGIST 
by enabling stratification for personalised therapeutic strategies and defining risks for other family members, 
according to the presence or absence of a germline SDHx mutation and or a SDHC epimutation.
Figure 4. Illustrates a proposed work flow for the investigation of SDHC promoter methylation in a clinical 
setting for (A) PPGL and (B) wtGIST (defined as a GIST with no identified somatic mutation in KIT, PDGFRA 
OR BRAF) *Next generation sequencing panel for PPGL including the genes; SDHA, SDHB, SDHC, SDHD, 
SDHAF2, FH, TMEM127, RET, VHL, MAX and including multiplex ligation dependent probe amplification 
for deletions and duplication. **Next generation sequencing panel for wtGIST including the genes; SDHA, 
SDHB, SDHC, SDHD, KIT, PDGFRA, NF1 and including multiplex ligation dependent probe amplification for 
deletions and duplication.
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Data Availability
Data is provided in the manuscript and/or Supplementary Data.
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